Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PL2200 + aspirin
- Development stage
- Unknown
- Lead developer
- PLx Pharma
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
PL2200 + aspirin is a combination drug consisting of acetylsalicylic acid (aspirin) pre-associated with phosphatidylcholine (a type of lipid). This formulation is designed to reduce the gastrointestinal (GI) toxicity commonly associated with standard aspirin therapy while maintaining its antiplatelet and anti-inflammatory effects. The mechanism of action remains primarily through irreversible inhibition of cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and reduced platelet aggregation. Preclinical and clinical studies suggest that PL2200 may offer similar or enhanced chemopreventive actions compared to regular low-dose aspirin, potentially making it more effective for cancer prevention and cardiovascular protection in at-risk populations. The addition of phosphatidylcholine aims to protect the GI mucosa by mitigating local injury caused by direct contact with aspirin[1][3][5].
- Brand names
- Aspertec
- Other names
- Aspirin-phosphatidylcholine complexlipid-based aspirin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on PL2200 + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PL2200 + aspirin.